Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary APS
Official title: Comparative Analysis of Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome
Run by New Valley University · NCT07142239 · Data updated 2026-11-12
This study tests whether blood markers MPV, PLR, and NLR differ between people with primary antiphospholipid syndrome and those with APS secondary to another autoimmune disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | New Valley University Academic / other |
| Locations | 1 site (Al Khārjah, Kharga Oasis) |
| Status | Recruiting |
| Started | November 27, 2025 |
| Main results expected | December 30, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | July 31, 2026 |
| Trial ID | NCT07142239 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older with a confirmed diagnosis of antiphospholipid syndrome (primary or secondary) based on updated Sydney criteria.
✕Probably not a fit
Patients with APS who have concurrent infections, hematologic malignancies, or recent platelet-altering treatments may not benefit from this observational analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study compares platelet and neutrophil-lymphocyte-derived markers in adults with antiphospholipid syndrome, focusing on differences between primary APS and APS that occurs with another autoimmune disease. Researchers will collect complete blood counts and calculate MPV, PLR, and NLR, along with antiphospholipid antibody profiles. The aim is to explore whether these easily measured blood tests reflect disease form and severity. The study does not involve an intervention and analyzes existing lab data to identify potential prognostic or diagnostic insights. Conducted at New Valley University in Khārjah and Kharga Oasis, the study excludes participants with active infections, hematologic malignancies, or recent platelet-altering medications.
Why it matters
Potential benefit: If successful, findings could help clinicians stratify APS patients using simple blood tests.
How similar studies have gone: Previous research has shown MPV, PLR, and NLR to be informative biomarkers in inflammatory and thrombotic conditions, supporting exploration in APS.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (age ≥18 years) * Diagnosis of APS based on updated Sydney classification criteria confirmed by: Clinical history of thrombosis and/or pregnancy morbidity, Persistent presence (≥12 weeks) of antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and/or lupus anticoagulant) Exclusion criteria: * Current infection or inflammatory condition unrelated to APS * Hematological malignancies or other blood disorders * Recent blood transfusion or platelet-altering medications other than APS treatments
Where it's running
-
New Valley University
Al Khārjah, Kharga Oasis, Egypt Recruiting
Study contacts
- Study coordinator: Asmaa Nady Hussein, MD
- Email: asmaanady_1010@med.nvu.edu.eg
- Phone: 01065161752
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Thrombocytopenia Trajectories in antiphospholipid syndrome
This study tests whether patterns in platelet counts over time can predict outcomes for adults with antiphospholipid syndrome.
-
BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases
This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.
-
Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies
Researchers are testing to see how autoreactive B cells behave in people with autoimmune diseases or immune deficiencies to better understand how these cells may contribute to disease.
-
YTS109 cell therapy for relapsed or treatment‑resistant autoimmune diseases
This will try a single infusion of YTS109 immune cells in adults 18–65 with relapsed or treatment‑resistant autoimmune diseases such as lupus, Sjogren’s, systemic sclerosis, inflammatory myopathies, or ANCA‑associated vasculitis.
-
YTS109 cell therapy for relapsed or refractory autoimmune diseases
This will try a single infusion of YTS109 immune cells to see if they are safe and help adults 18–65 with relapsed or refractory lupus (including lupus nephritis), Sjogren's syndrome, inflammatory myopathy, or ANCA‑associated vasculitis.
-
Antiphospholipid syndrome in people 65 and older who had an ischemic stroke
This study will test whether routine blood testing for antiphospholipid antibodies in people aged 65 and over hospitalized with ischemic stroke or TIA can identify previously unrecognized antiphospholipid syndrome.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.